Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI

被引:69
作者
Chinnasamy, Dhanalakshmi
Milsom, Michael D.
Shaffer, James
Neuenfeldt, James
Shaaban, Aimen F.
Margison, Geoffrey P.
Fairbairn, Leslie J.
Chinnasamy, Nachimuthu
机构
[1] Aurora St Lukes Med Ctr, Vince Lombardi Gene Therapy Lab, Immunotherapy Program, Milwaukee, WI 53215 USA
[2] Christie Hosp NHS Trust, Canc Res UK, Gene Therapy Grp, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England
[3] Univ Wisconsin, Dept Surg, Madison, WI 53792 USA
[4] Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res UK, Carcinogenesis Grp, Manchester M20 4BX, Lancs, England
[5] Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA
关键词
D O I
10.1186/1743-422X-3-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: A number of gene therapy applications would benefit from vectors capable of expressing multiple genes. In this study we explored the feasibility and efficiency of expressing two or three transgenes in HIV-1 based lentiviral vector. Bicistronic and tricistronic self-inactivating lentiviral vectors were constructed employing the internal ribosomal entry site (IRES) sequence of encephalomyocarditis virus (EMCV) and/or foot-and-mouth disease virus (FMDV) cleavage factor 2A. We employed enhanced green fluorescent protein (eGFP), O-6-methylguanine-DNA-methyltransferase (MGMT), and homeobox transcription factor HOXB4 as model genes and their expression was detected by appropriate methods including fluorescence microscopy, flow cytometry, immunocytochemistry, biochemical assay, and western blotting. Results: All the multigene vectors produced high titer virus and were able to simultaneously express two or three transgenes in transduced cells. However, the level of expression of individual transgenes varied depending on: the transgene itself; its position within the construct; the total number of transgenes expressed; the strategy used for multigene expression and the average copy number of pro-viral insertions. Notably, at limiting MOI, the expression of eGFP in a bicistronic vector based on 2A was similar to 4 times greater than that of an IRES based vector. Conclusion: The small and efficient 2A sequence can be used alone or in combination with an IRES for the construction of multicistronic lentiviral vectors which can express encoded transgenes at functionally relevant levels in cells containing an average of one pro-viral insert.
引用
收藏
页数:16
相关论文
共 34 条
[1]   Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters [J].
Amendola, M ;
Venneri, MA ;
Biffi, A ;
Vigna, E ;
Naldini, L .
NATURE BIOTECHNOLOGY, 2005, 23 (01) :108-116
[2]   Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins [J].
Chinnasamy, D ;
Chinnasamy, N ;
Enriquez, MJ ;
Otsu, M ;
Morgan, RA ;
Candotti, F .
BLOOD, 2000, 96 (04) :1309-1316
[3]   Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide [J].
Chinnasamy, D ;
Fairbairn, LJ ;
Neuenfeldt, J ;
Treisman, JS ;
Hanson, JP ;
Margison, GP ;
Chinnasamy, N .
HUMAN GENE THERAPY, 2004, 15 (08) :758-769
[4]   Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors [J].
Chinnasamy, N ;
Chinnasamy, D ;
Toso, JF ;
Lapointe, R ;
Candotti, F ;
Morgan, RA ;
Hwu, P .
HUMAN GENE THERAPY, 2000, 11 (13) :1901-1909
[5]   Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy [J].
de Felipe, P ;
Martín, V ;
Cortés, ML ;
Ryan, M ;
Izquierdo, M .
GENE THERAPY, 1999, 6 (02) :198-208
[6]   Targeting of proteins derived from self-processing polyproteins containing multiple signal sequences [J].
de Felipe, P ;
Ryan, MD .
TRAFFIC, 2004, 5 (08) :616-626
[7]   Tricistronic and tetracistronic retroviral vectors for gene transfer [J].
De Felipe, P ;
Izquierdo, M .
HUMAN GENE THERAPY, 2000, 11 (13) :1921-1931
[8]   Stable antibody expression at therapeutic levels using the 2A peptide [J].
Fang, JM ;
Qian, JJ ;
Yi, SL ;
Harding, TC ;
Tu, GH ;
VanRoey, M ;
Jooss, K .
NATURE BIOTECHNOLOGY, 2005, 23 (05) :584-590
[9]   Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons [J].
Furler, S ;
Paterna, JC ;
Weibel, M ;
Büeler, H .
GENE THERAPY, 2001, 8 (11) :864-873
[10]   LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 [J].
Hacein-Bey-Abina, S ;
Von Kalle, C ;
Schmidt, M ;
McCcormack, MP ;
Wulffraat, N ;
Leboulch, P ;
Lim, A ;
Osborne, CS ;
Pawliuk, R ;
Morillon, E ;
Sorensen, R ;
Forster, A ;
Fraser, P ;
Cohen, JI ;
de Saint Basile, G ;
Alexander, I ;
Wintergerst, U ;
Frebourg, T ;
Aurias, A ;
Stoppa-Lyonnet, D ;
Romana, S ;
Radford-Weiss, I ;
Gross, F ;
Valensi, F ;
Delabesse, E ;
Macintyre, E ;
Sigaux, F ;
Soulier, J ;
Leiva, LE ;
Wissler, M ;
Prinz, C ;
Rabbitts, TH ;
Le Deist, F ;
Fischer, A ;
Cavazzana-Calvo, M .
SCIENCE, 2003, 302 (5644) :415-419